Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 7;5(3):402-405.
doi: 10.1016/j.jaccao.2022.12.008. eCollection 2023 Jun.

Genetic Predisposition to Cardiovascular Disease in Patients With Cancer: A Clinical Perspective

Dimitrios Farmakis  1   2 , Georgios Papingiotis  2 , Gerasimos Filippatos  2
Affiliations
Editorial

Genetic Predisposition to Cardiovascular Disease in Patients With Cancer: A Clinical Perspective

Dimitrios Farmakis et al. JACC CardioOncol. .
No abstract available

Keywords: anthracycline; cancer survivorship; genomics.

PubMed Disclaimer

Conflict of interest statement

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
Genetic Predisposition to Cardiovascular Disease in Cancer: Implications and Potentials Genetic variants may render cancer patients more prone to cardiotoxicity from anticancer therapies; may further increase the susceptibility to cancer-related cardiovascular complications, such as thromboembolic complications; and may predispose to concomitant cancer and cardiovascular disease (CVD) development, as with clonal hematopoiesis of indeterminate potential mutations. Knowledge of the impact of the genetic background on the risk of cardiovascular disease may allow a more personalized approach to anticancer therapy based on cardiotoxicity risk, the identification of new targets for cardiotoxicity prevention, and further prevention strategies to prevent cancer-related cardiovascular complications strategies (eg, anticoagulation prophylaxis) and even to mitigate the risk of cardiovascular disease and cancer in the general population. See text for details.
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jaccao.2022.09.009

References

    1. Farmakis D., Keramida K., Filippatos G. How to build a cardio-oncology service? Eur J Heart Fail. 2018;20:1732–1734. - PubMed
    1. Farmakis D. Is cardio-oncology a rapidly growing field of precision medicine? Eur J Heart Fail. 2020;22:2310–2313. - PubMed
    1. Lyon A.R., López-Fernández T., Couch L.S., et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J. 2022;43:4229–4361. - PubMed
    1. Lyon A.R., Dent S., Stanway S., Earl H., et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945–1960. - PMC - PubMed
    1. Farmakis D., Mantzourani M., Filippatos G. Anthracycline-induced cardiomyopathy: secrets and lies. Eur J Heart Fail. 2018;20:907–909. - PubMed

Publication types

LinkOut - more resources